Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

An ability to activate latent human immunodeficiency virus type 1 (HIV-1) expression could benefit many HIV cure strategies; however, most latency-reversing agents (LRAs) have proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Virol
Auteurs principaux: Gramatica, Andrea, Schwarzer, Roland, Brantley, William, Varco-Merth, Benjamin, Sperber, Hannah S., Hull, Philip A., Montano, Mauricio, Migueles, Stephen A., Rosenthal, Danielle, Hogan, Louise E., Johnson, Jeffrey R., Packard, Thomas A., Grimmett, Zachary W., Herzig, Eytan, Besnard, Emilie, Nekorchuk, Michael, Hsiao, Feng, Deeks, Steven G., Snape, Michael, Kiernan, Bernard, Roan, Nadia R., Lifson, Jeffrey D., Estes, Jacob D., Picker, Louis J., Verdin, Eric, Krogan, Nevan J., Henrich, Timothy J., Connors, Mark, Ott, Melanie, Pillai, Satish K., Okoye, Afam A., Greene, Warner C.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2021
Sujets:
Vaccines and Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8103695/
https://ncbi.nlm.nih.gov/pubmed/33536176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02393-20
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires